🔗 Share this article

As the United States proceeds with historic changes to its immunization schedules, an unexpected name has emerged unexpectedly: Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by casting doubt on Covid shots in the pandemic and has focused upon alleged fatalities following Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Schedule

Agency leaders were set to announce sweeping changes to the childhood vaccination calendar in December, bringing the US with the Danish vaccine program, sources say – a significant shift that would put the US at odds with many the global community with little proof for improved outcomes. The planned update has been postponed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the division this calendar year.

A Shift at the Regulatory Body

The acting appointment could signify a strengthened alliance between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon dismantling already-approved immunizations at the FDA.

Høeg has repeatedly called for discontinuing some childhood immunization guidelines in the US in order to be more like Denmark's approach, a society with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

So far comments, she has continued to focus on vaccination policy – traditionally the purview of Dr. Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Background

The appointee has little discernible background in pharmaceutical research, regulation or management, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a large organization. She lacks background in pharmaceutical oversight.”

Previous directors of CBER would “grasp laws and regulations and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who ran the center have had.”

The drug center has an vast workload at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the innovative therapies, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and every single one need to be looked after,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial administrative element to the position, which manages over 5,000 employees. “It’s a huge management job, if you perform it correctly,” she said.

Response and Disputed Initiatives

When asked about concerns about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a representative stated that the “concerns are based on flawed assumptions”.

“Her resume aligns with the duties of her job,” the official said, noting the period Høeg spent advising the agency head on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg takes over the commissioner’s new fast-track approval initiative, a contentious rapid therapy clearance system that apparently concerned her former heads. “By what process are these medications being chosen for this voucher program? Who makes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he remarked, “the agency appears to be shifting towards laxer rules of most medications, aside from vaccines.”

Documented History on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if problematic, history, critics observe. She authored a analysis using unconfirmed public submissions to estimate the incidence of heart inflammation following Covid immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the current federal leadership encompassed changing rules for novel immunizations and discontinuing “non-essential” vaccines, she stated following the vote on a podcast. At the FDA, Høeg has reportedly suggested preventing teenage boys from receiving Covid vaccines.

“She’s an thorough true believer who begins with her beliefs and works backwards to retrofit the science in a very deceptive, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow contrarians, {like|